- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
"Not So Different": How a Value-Based Pathway Led to Increased Biosimilar Use
This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.
It's no secret that biosimilars that treat inflammatory diseases have struggled to gain ground in the United States, with few products launched relative to those approved, low uptake of the products that are available, and formulary restrictions that sometimes favor branded biologics over biosimilar options. But given the benefits that biosimilars can provide, some physicians are taking matters into their own hands with concerted efforts to bring these products to the clinic. This week on the podcast, we're speaking with Colin C. Edgerton, MD. He's one of the founding members of Articularis Healthcare Group, which has created a value-based rheumatoid arthritis treatment pathway that has boosted biosimilar use.
Read more about the value-based pathway here, and find the Articularis Rheumatology Network here.
Can Global Policies to Boost Biosimilar Adoption Work in the US?
November 17th 2024On this special episode of Not So Different honoring Global Biosimilars Week, Craig Burton, executive director of the Biosimilars Council, explores how global policies—from incentives to health equity strategies—could boost biosimilar adoption in the US.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Biosimilars Gastroenterology Roundup for February 2023—Podcast Edition
March 5th 2023On this episode of Not So Different, we chronicle the latest gastroenterology news from February, including several updates on adalimumab and infliximab biosimilars and industry analyses on the utilization of these drugs and patient confidence in gastroenterologists’ recommendations.
